DelMar starts Phase II of VAL-083 for MGMT-unmethylated GBM

DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) began a Phase II trial of VAL-083 to treat newly diagnosed O6-alkylguanine alkyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM).

The open-label, Chinese trial will enroll 20-30 patients in sequential dose-escalation cohorts to receive 20, 30 or 40 mg/m² IV VAL-083 every 3 weeks in combination with radiotherapy. The primary endpoint is progression-free survival (PFS). Secondary endpoints include safety and pharmacokinetics. DelMar expects safety and efficacy data within 9 and 15 months, respectively...